Cognition Therapeutics, Inc. Repayments of Short-term Debt
Cognition Therapeutics, Inc. (CGTX) reported Repayments of Short-term Debt of $229.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfShortTermDebt · last filed 2026-08-07
- Cognition Therapeutics, Inc. repayments of short-term debt for the quarter ending 2026-06-30 was $116.00K, a 3.33% decline year-over-year.
- Cognition Therapeutics, Inc. repayments of short-term debt for the quarter ending 2026-03-31 was $113.00K, a 4.24% decline year-over-year.
- Cognition Therapeutics, Inc. repayments of short-term debt for the quarter ending 2025-12-31 was $74.00K, a 62.05% decline year-over-year.
- Cognition Therapeutics, Inc. repayments of short-term debt for the quarter ending 2025-09-30 was $41.00K, a 77.84% decline year-over-year.
- Cognition Therapeutics, Inc. repayments of short-term debt for fiscal 2025 was $353.00K, a 52.23% decline from fiscal 2024.
- Cognition Therapeutics, Inc. repayments of short-term debt for fiscal 2024 was $739.00K, a 8.88% decline from fiscal 2023.
- Cognition Therapeutics, Inc. repayments of short-term debt for fiscal 2023 was $811.00K, a 41.91% decline from fiscal 2022.
- Cognition Therapeutics, Inc. repayments of short-term debt for fiscal 2022 was $1.40M, a 420.90% increase from fiscal 2021.
| Period end | Repayments of Short-term Debt 3 month | Repayments of Short-term Debt 6 month | Repayments of Short-term Debt 9 month | Repayments of Short-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $229.00K 10-Q · filed 2026-08-07 | $303.00K derived: sum of 3 quarters · filed 2026-08-07 | $344.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $113.00K 10-Q · filed 2026-05-08 | $187.00K derived: sum of 2 quarters · filed 2026-05-08 | $228.00K derived: sum of 3 quarters · filed 2026-05-08 | $348.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $115.00K derived: sum of 2 quarters · filed 2026-03-26 | $235.00K derived: sum of 3 quarters · filed 2026-08-07 | $353.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $161.00K derived: sum of 2 quarters · filed 2026-08-07 | $279.00K 10-Q · filed 2025-11-06 | $474.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $238.00K 10-Q · filed 2026-08-07 | $433.00K derived: sum of 3 quarters · filed 2026-08-07 | $618.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $118.00K 10-Q · filed 2026-05-08 | $313.00K derived: sum of 2 quarters · filed 2026-05-08 | $498.00K derived: sum of 3 quarters · filed 2026-05-08 | $679.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $380.00K derived: sum of 2 quarters · filed 2026-03-26 | $561.00K derived: sum of 3 quarters · filed 2026-03-26 | $739.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $366.00K derived: sum of 2 quarters · filed 2025-11-06 | $544.00K 10-Q · filed 2025-11-06 | $723.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $359.00K 10-Q · filed 2025-08-07 | $538.00K derived: sum of 3 quarters · filed 2025-08-07 | $753.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $178.00K 10-Q · filed 2025-05-07 | $357.00K derived: sum of 2 quarters · filed 2025-05-07 | $572.00K derived: sum of 3 quarters · filed 2025-05-07 | $782.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $394.00K derived: sum of 2 quarters · filed 2025-03-20 | $604.00K derived: sum of 3 quarters · filed 2025-03-20 | $811.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $425.00K derived: sum of 2 quarters · filed 2024-11-13 | $632.00K 10-Q · filed 2024-11-13 | $837.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $417.00K 10-Q · filed 2024-08-08 | $622.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.02M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $207.00K 10-Q · filed 2024-05-07 | $412.00K derived: sum of 2 quarters · filed 2024-05-07 | $813.00K derived: sum of 3 quarters · filed 2024-05-07 | $1.21M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $606.00K derived: sum of 2 quarters · filed 2024-03-26 | $1.00M derived: sum of 3 quarters · filed 2024-03-26 | $1.40M 10-K · filed 2024-03-26 |
| 2022-09-30 | $401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $797.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.19M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $790.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $394.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $268.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |